Correction: Overcoming chemoresistance in esophageal cancer with synergistic strategies - Report - MDSpire

Correction: Overcoming chemoresistance in esophageal cancer with synergistic strategies

  • By

  • Chunxiao Gao

  • Ting Zhang

  • Guangyuan Li

  • Weishan Zhang

  • Honglin Chen

  • Diefei Li

  • Jixuan Xu

  • Mengxue Li

  • Ruihong Wang

  • Yamin Xing

  • Jian Zhan

  • Zhentai Ren

  • Xia Xue

  • Wulong Liang

  • Xiangdong Sun

  • Xiaojuan Zhang

  • Xinfeng Liang

  • Hongqiao Zhan

  • Zisen Zhang

  • Xiufeng Chu

  • July 3, 2026

  • 0 min

Share

Clinical Report: Correction on Overcoming Chemoresistance in Esophageal Cancer

Background

Esophageal cancer presents significant treatment challenges due to chemoresistance, which can arise from tumor cell adaptations and changes in the tumor microenvironment. Understanding and addressing these mechanisms is crucial.

Data Highlights

No numerical or trial data presented in the source material.

Key Findings

  • The correction clarified that chemotherapy is a fundamental component of current combination therapies.
  • CD8+ T cells are impaired in esophageal cancer due to immune checkpoint molecule expression.
  • P-gp inhibitors are being explored to overcome drug efflux in esophageal cancer.
  • Platinum-based agents cause DNA damage, which tumor cells counteract through DNA damage response mechanisms.
  • Supplementary Table 1 was published to provide additional data relevant to the study.

Clinical Implications

The corrections highlight the importance of accurate communication regarding chemotherapy's role in treatment strategies for esophageal cancer. Clinicians should remain informed about ongoing research into overcoming chemoresistance through combination therapies.

Conclusion

The corrections made to the original article enhance the clarity and accuracy of the information regarding chemoresistance in esophageal cancer. Continued research in this area is essential for improving treatment outcomes.

Related Resources & Content

  1. Gao C, Zhang T, Li G, et al., Frontiers in Immunology, 2026 -- Correction: Strategies to Address Chemoresistance in Esophageal Cancer through Synergistic Approaches
  2. BJS (British Journal of Surgery) — Evolving Approaches to Multimodal Therapy for Locally Advanced Oesophageal and Junctional Adenocarcinoma
  3. Frontiers in Oncology — Feasibility and strategy analysis of radiotherapy consolidation following immunotherapy for stage IV esophageal squamous cell carcinoma
  4. Updates in Surgery — Efficacy of Targeted and Immunotherapy Approaches in Patients with Advanced Esophageal and Esophago-Gastric Junction Cancer, Both Metastatic and Non-Metastatic
  5. Evolving Approaches to Multimodal Therapy for Locally Advanced Oesophageal and Junctional Adenocarcinoma
  6. Feasibility and strategy analysis of radiotherapy consolidation following immunotherapy for stage IV esophageal squamous cell carcinoma
  7. Efficacy of Targeted and Immunotherapy Approaches in Patients with Advanced Esophageal and Esophago-Gastric Junction Cancer
  8. Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline Update
  9. Overcoming chemoresistance in esophageal cancer with synergistic strategies

Original Source(s)

Correction: Overcoming chemoresistance in esophageal cancer with synergistic strategies

  • by Chunxiao Gao, Ting Zhang, Guangyuan Li, Weishan Zhang, Honglin Chen, Diefei Li, Jixuan Xu, Mengxue Li, Ruihong Wang, Yamin Xing, Jian Zhan, Zhentai Ren, Xia Xue, Wulong Liang, Xiangdong Sun, Xiaojuan Zhang, Xinfeng Liang, Hongqiao Zhan, Zisen Zhang, Xiufeng Chu

  • July 3, 2026

Related Content

Factors associated with relapse/progression in pediatric trunk and extremity rhabdomyosarcoma

Incidental thyroid carcinoma in surgically treated multinodular goiter: a retrospective study

Dendritic cells in cancer immunotherapy: functional barriers, reprogramming strategies and translational challenges